MEDIHA SÜLEYMANOGLU

Dr. MEDIHA SÜLEYMANOGLU

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
PDF file
MSMEDIHA SÜLEYMANOGLU
MEDIHA SÜLEYMANOGLU
SKSerap erdem kuruca
Serap erdem kuruca
TBTülay Bal‐Demirci
Tülay Bal‐Demirci
NÖNamık Özdemir
Namık Özdemir
BÜBahri Ülküseven
Bahri Ülküseven
IYIlhan Yaylim
Ilhan Yaylim

8 August 2019 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
PDF file
MSMEDIHA SÜLEYMANOGLU
MEDIHA SÜLEYMANOGLU
BKBusra Kaya
Busra Kaya
SESerap Erdem‐Kuruca
Serap Erdem‐Kuruca
BÜBahri Ülküseven
Bahri Ülküseven

22 February 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
FAFigen Abatay-Sel
Figen Abatay-Sel
AEAyşe Erol
Ayşe Erol
MSMEDIHA SÜLEYMANOGLU
MEDIHA SÜLEYMANOGLU
GDGokhan Demirayak
Gokhan Demirayak
CKCigdem Kekik-Cinar
Cigdem Kekik-Cinar
FOFatma Savran Oguz
Fatma Savran Oguz

20 March 2023 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
AEAyşe Erol
Ayşe Erol
FSFigen Abatay Sel
Figen Abatay Sel
MSMEDIHA SÜLEYMANOGLU
MEDIHA SÜLEYMANOGLU
GDGökhan Demirayak
Gökhan Demirayak
SKSerap erdem kuruca
Serap erdem kuruca
FOFatma Savran Oguz
Fatma Savran Oguz

29 April 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MSMEDIHA SÜLEYMANOGLU
MEDIHA SÜLEYMANOGLU
ABAyşe Erol Bozkurt
Ayşe Erol Bozkurt
FSFigen Abatay Sel
Figen Abatay Sel
IÖİsA Aykut Özdemir
İsA Aykut Özdemir
FOFatma Savran Oğuz
Fatma Savran Oğuz
MÖMustafa Oral Öncül
Mustafa Oral Öncül

1 November 2023 in Current Stem Cell Research & Therapy
Verified
Journal Article
Closed access
PDF file
FAFigen Abatay-Sel
Figen Abatay-Sel
AEAyşe Erol
Ayşe Erol
MSMEDIHA SÜLEYMANOGLU
MEDIHA SÜLEYMANOGLU
GDGokhan Demirayak
Gokhan Demirayak
CKCigdem Kekik-Cinar
Cigdem Kekik-Cinar
FOFatma Savran Oguz
Fatma Savran Oguz
Background: Colorectal cancer (CRC) is the third most common cancer worldwide. Recently, mesenchymal stem cells (MSCs) have been considered a suitable cell therapy option for cancer due to their high migration rate to the tumor site. Objectives: The study aimed to compare the effects of human umbilical cord blood derived-MSC (UCMSC) and human Wharton’s Jelly derived-MSC (WJ-MSC) on the HT-29 cell line. Methods: UC-MSC was obtained by Ficoll-Paque density gradient and WJ-MSC by explant method. The characterizations of MSCs and apoptosis assays were performed by flow cytometry, and caspase-3 protein levels were measured by ELISA. Results: After 72 hours of HT-29 cancer cells incubation, it was indicated that WJ-MSC was more effective at 1:5 and 1:10 ratios. Similar results were found for caspase-3 by ELISA. Moreover, WJ-MSC (1:5, p < 0.006; 1:10, p < 0.007) was found to be more effective at both doses compared to UC-MSC. Conclusion: In this study, we used two different MSC sources at two different ratios to evaluate the apoptotic effect of MSC in vitro on HT-29 CRC cells. As a result, WJ-MSC indicated a more apoptotic effect on HT-29 cells compared to CB-MSC. We anticipated that this preliminary in vitro study would be extended in future in vitro/in vivo studies. Moreover, investigating the behavior of MSC in colorectal tumor microenvironment will be beneficial for the stem cell therapy approach.